- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02158117
Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use
February 2, 2017 updated by: Norwegian University of Science and Technology
Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway.
The annual death toll from overdose is about 250, twice the annual death toll from traffic accidents.
Those who inject heroin or other opioids are considered to have the highest risk for death from overdose.
To save lives, immediate treatment with a μ-opioid antidote such as naloxone is required.
Usually naloxone is injected into a muscle or a blood vessel.
Administration of naloxone via the nose has been suggested as an alternative for use by emergency teams and possibly also bystanders.
This is not only an easier way to give naloxone, but would also eliminate the risk for needle stick injuries and blood contamination.
A pilot study in this hospital has shown no significant side effects or adverse reaction.
While significant benefits are expected from developing an adequately formulated naloxone nasal spray for pre-hospital use, the risks to participants are minimal.
Therefore this preclinical study in healthy volunteers will be undertaken.
Study Overview
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Trondheim, Norway
- Department of Circulation and Medical Imaging
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy
- Normal electrocardiogram (ECG)
- Hemoglobin: male 13.4 - 17.0 g/dL, female 11,7- 15.3 g/dL
- Creatinine: male 60- 105 micromol/L female 45- 90 micromol/L
- ASAT: male 15- 45 U/L, female 15- 35 U/L
- ALAT: male 10- 70 U/L female 10- 45 U/L
- Gamma GT: male 10- 80 U/L female 10- 45 U/L
- HCG normal under 3 ye/L
- Fertile women must use safe contraception and have a negative serum HCG at inclusion
Exclusion Criteria:
- Taking any medications including herbal medicines the last week prior to first treatment visit
- History of drug abuse
- History of prior drug allergy
- Having any local nasal disease or nasal surgery or recent cold for the last week
- Pregnancy
- Fertile women not using high efficacy contraceptives (Oral contraceptives, Patch (Evra), Implants, Vaginal ring, Hormonal IUD, Copper IUD, Sterilization) throughout the study period until their last visit.
- Lactating women
- Any reason why, in the opinion of the investigator, the patient should not participate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: nasal naloxone
8 and 16 mg/ml, comparator 1 mg/ml.
Three daily occasions with at least 3 days washout between treatment (min 8 days).
|
one puff in one nostril with the subject is lying down
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
bioavailability of naloxone
Time Frame: 2 weeks
|
A LCMSMS method for determination of Naloxone in serum was developed using acetonitrile protein precipitation.
Naloxone D5 was used as internal standard and quantitative determination was done by using Sciex Analyst version 1.5.
The method is fully validated by assessing linearity, accuracy, precision, sensitivity, specificity/selectivity, in process and storage stability, dilution integrity and assay ruggedness according to Dadgar (1995) and Shah (1991).
The method was found linear, accurate and precise across the dynamic range of 0.05 to 45 ng/ml.
Limit of quantification (LOQ) was 0.05ng/ml with CV = 12.7% and inaccuracy < 7.8% (n = 17).
Quality Controls (QC) in middle (n=18) and upper (n=18) calibration range had CV < 4.2% and inaccuracy <8.2 %
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum serum concentration (Cmax)
Time Frame: 2 weeks
|
2 weeks
|
|
Time to maximum serum concentration (Tmax)
Time Frame: 2 weeks
|
2 weeks
|
|
adverse events
Time Frame: 2 weeks
|
will be reported from the start of the first session to the follow-up visit.
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
November 1, 2014
Study Registration Dates
First Submitted
June 2, 2014
First Submitted That Met QC Criteria
June 4, 2014
First Posted (Estimate)
June 6, 2014
Study Record Updates
Last Update Posted (Estimate)
February 3, 2017
Last Update Submitted That Met QC Criteria
February 2, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPI-13-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Overdose
-
NHS Greater Glasgow and ClydePublic Health ScotlandRecruitingDrug Effect | Drug Use | Drug Abuse | Drug Toxicity | Illicit Drug Use | Overdose, Drug | Illicit Drug Overdose | Illicit Drug IntoxicationUnited Kingdom
-
Emergent BioSolutionsCompletedOpioid OverdoseUnited States
-
Oregon Health and Science UniversityOregon State University; Oregon Department of Corrections; CODA Inc.; Bridgeway... and other collaboratorsActive, not recruiting
-
University Hospital Bispebjerg and FrederiksbergCompletedDrug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
San Francisco Department of Public HealthRecruitingStimulant Overdose | Overdose Accidental | Overdose Cocaine | Overdose MethamphetamineUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Substance Abuse | Drug Overdose | Drug Abuse | Drug AddictionUnited States
-
Mikkel Bring ChristensenCompletedBlood Pressure | Drug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
Pusan National University Yangsan HospitalCompletedGeneral Anesthetic Drug OverdoseKorea, Republic of
-
Brown UniversityNational Institute on Drug Abuse (NIDA)CompletedDrug Overdose | Opioid OverdoseUnited States
-
Johns Hopkins Bloomberg School of Public HealthNational Institute on Drug Abuse (NIDA)Not yet recruiting
Clinical Trials on nasal naloxone
-
Pocket Naloxone CorpCompleted
-
State University of New York - Upstate Medical...Binghamton UniversityCompletedHarm Reduction | Opioid-use Disorder | NaloxoneUnited States
-
Food and Drug Administration (FDA)Spaulding Clinical Research LLCCompletedClinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal NaloxoneHealthy Subjects | Pharmacokinetics | Opioid AntagonistUnited States
-
INSYS Therapeutics IncCompleted
-
INSYS Therapeutics IncCompleted
-
Finnish Institute for Health and WelfareUnknownNaloxone | Gambling Disorder | Opioid Antagonist | Pathological GamblingFinland
-
Leiden University Medical CenterU.S. Food and Drug Administration (FDA)RecruitingChronic Opioid Use | Opioid Induced Respiratory DepressionNetherlands
-
University of MinnesotaTerminatedType 1 Diabetes | Hypoglycemia UnawarenessUnited States
-
Emergent BioSolutionsCompletedOpioid OverdoseUnited States
-
Johns Hopkins UniversityCure Addiction NowRecruitingOpioid Use DisorderUnited States